food companies glp-1 Crafting product claims in the weight-loss drug era GLP-1 Use and Its Impact

The top six most common gastrointestinal reports were nausea (8,988, 42.23%), diarrhea (4,666, 21.93%), vomiting (4,660, 21.90%), upper abdominal pain (2,082, 9.78%), constipation (1,790, 8.41%), and pancreatitis (1,752, 8.23%)

Thank you for this - very useful as we are looking at how low calorie high nutrient density fits into the RTE market

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide in non-diabetic patients with obesity and prior cardiovascular events [4,5]

In comparison, no case of pancreatitis was reported in the placebo group

Note: the effects are mild to modest as compared to injectables & topical retinoids

Diabetes Metab Res Rev (2011) 27:28697